

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

In Vitro Metabolic Profile and *In Vivo* Antischistosomal Activity Studies of (η^6 - Praziquantel)Cr(CO)₃ Derivatives

23
24
25
26
27
28

Malay Patra,^a Katrin Ingram,^b Anna Leonidova,^a Vanessa Pierroz,^{a,c} Stefano Ferrari,^c Murray N.

Robertson,^d Matthew H. Todd,^d Jennifer Keiser,^{b,} Gilles Gasser^{a,*}*

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

[^a] Institute of Inorganic Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland; [^b] Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland; [^c] Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland; [^d] School of Chemistry, The University of Sydney, NSW 2006, Australia.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT. The *in vitro* metabolic behavior was investigated of two chromium tricarbonyl derivatives of the antischistosomal drug Praziquantel (PZQ) with the formula $(\eta^6\text{-PZQ})\text{Cr}(\text{CO})_3$ (**1** and **2**), using human liver microsomes. It could be demonstrated that the metabolic profiles of the derivatives differ significantly. The optically pure $(\eta^6\text{-PZQ})\text{Cr}(\text{CO})_3$ derivatives, (*S*, *Sp*)-**1**, (*R*, *Rp*)-**1**, (*S*, *Rp*)-**2** and (*R*, *Sp*)-**2**, were also prepared to assess of the eudysmic ratios of **1** and **2** against *S. mansoni*. A strong enantioselective antischistosomal activity was observed. The *R*-enantiomers are highly active against adult schistosomes *in vitro* (IC_{50} : 0.08 - 0.13 μM) whereas both *S*-enantiomers lack activity. The *in vivo* activity of **1** and **2** was then studied in mice harboring a chronic *Schistosoma mansoni* (*S. mansoni*) infection. A single dose of **1** and **2** (400 mg/kg) resulted in low worm burden reductions of 24 and 29 % ($p > 0.05$).

Introduction.

Schistosomiasis is the second most prevalent parasitic disease in the world after malaria with 207 million people infected each year. Surprisingly there is only one available drug on the market to treat the disease, Praziquantel (PZQ) (Figure 1).^{1, 2} Despite the identification of various lead antischistosomal compounds, no new drugs have entered the market since the development of PZQ in 1970s.³ Reliance on a single drug is dangerous and reduced susceptibility of *Schistosoma mansoni* (*S. mansoni*) to PZQ has already been noted in the field.⁴⁻⁶ The important limitations of PZQ make the situation even more precarious. PZQ has low metabolic stability *in vivo*^{7, 8} and lacks activity against the juvenile stage of *Schistosoma*.⁹ Taken together, these facts are a strong indication that novel drugs to treat schistosomiasis are required. With this in mind, our groups have recently embarked on a project to study the potential of organometallic-containing PZQ derivatives as antischistosomal agents. This concept originates from the pioneering work of Jaouen, Biot and co-workers on organometallic derivatives of the anticancer agent Tamoxifen (Ferrocifens) and the antimalarial Chloroquine (Ferroquine).^{10, 11} For both Ferrocifens and Ferroquine, the addition of a ferrocenyl moiety into the known organic drug allowed the addition of novel modes of action to the parent compounds.^{12, 13} Encouraged by these results, we investigated the antischistosomal activity of 18 ferrocenyl derivatives of PZQ.¹⁴ Unfortunately, only moderate *in vitro* activity could be determined.¹⁴ On the other hand, it was found that two (η^6 -PZQ)Cr(CO)₃ derivatives (**1** and **2**, Figure 1) had *in vitro* activity against *S. mansoni* comparable to PZQ (nanomolar range).¹⁵ These promising *in vitro* data persuaded us to study in more detail the *in vivo* behavior of **1** and **2**. Clearly a promising *in vitro* activity of a drug candidate cannot always be extrapolated into a good *in vivo* activity since the pharmacokinetics and metabolism profile of a drug are key determinants for its *in vivo* success. It is therefore

1
2
3
4
5
6 important to assess the metabolic fate of a drug candidate. As a continuation of our development
7
8 on the (η^6 -PZQ)Cr(CO)₃ derivatives, we present herein the in-depth *in vitro* metabolic behavior
9
10 of these chromium derivatives as well as their antischistosomal activity in mice infected with
11
12 adult *S. mansoni*. Importantly, we could demonstrate, by preparing optically active (*S*, *Sp*)-**1**, (*R*,
13
14 *Rp*)-**1**, (*S*, *Rp*)-**2** and (*R*, *Sp*)-**2** that, as for the parent drug PZQ, the (η^6 -PZQ)Cr(CO)₃ derivatives
15
16 exhibit enantioselective *in vitro* antischistosomal activity.
17
18
19
20
21




Figure 1. Structures of PZQ, (η^6 -PZQ)Cr(CO)₃ derivatives **1** and **2**. Note that all the compounds presented are racemic mixtures.

Results and Discussion.

***In Vitro* Metabolism Studies.** In order to gain insight into the metabolic fate of the racemic (η^6 -PZQ)Cr(CO)₃ derivatives **1** and **2**, we investigated their *in vitro* metabolic behavior using human liver microsomes. Accordingly **1**, **2** and PZQ were incubated with human liver microsomes in the presence of NADPH at 37 °C (see SI for details). Diazepam which is (known to be stable in human liver microsomes) was used as a positive control. After incubation, compounds were immediately extracted with dichloromethane which was evaporated to provide residues that were analyzed using LC-MS. The metabolites were identified by comparing the differences in the respective *m/z* values in MS spectra with those determined for the parent compound (**1** or **2**) and PZQ (see Table S1, S2 for details). The identities of the major metabolites were further

1
2
3
4
5
6 confirmed by comparing the retention time in the UV trace and the mass spectrum from the LC-
7 MS analysis of authentic samples (*vide infra*). Semi-quantitative analysis of the ratio of parent
8 compound and different metabolites present in the mixture after post incubation with human
9 liver microsomes was achieved by comparing the areas under the respective peaks of different
10 compounds visible in the UV traces of the LC analysis (see Table S3 for details).
11
12

13
14
15
16
17 In the case of **1**, formation of two major and three minor metabolites was observed (see Figure 2
18 and Table S1 and S3). After 2.5 h a considerable amount (*ca.* 50 %) of **1** remained unchanged in
19 the mixture; the most abundant metabolites, **1.M1** and **1.M2** (22 and 15 %, respectively), were
20 detected at retention times of 12.8 and 9.1 minutes, respectively, by LC-MS (positive ion
21 electrospray mode). The corresponding MS spectrum for the **1.M1** peak provided base peaks at
22 $m/z = 313.2$ and 335.2 which fit with the species $[\text{PZQ}+\text{H}]^+$ and $[\text{PZQ}+\text{Na}]^+$ (MW of PZQ
23 312.2), respectively. **1.M1** was therefore identified as PZQ that is formed by loss of the $\text{Cr}(\text{CO})_3$
24 moiety of **1**. This identification was further confirmed by comparing the LC and MS traces of an
25 authentic sample of PZQ (Figure S1 in SI). The metabolite **1.M2** was identified as a mono-
26 hydroxylated species of PZQ (PZQ-OH) from the peaks at $m/z = 329.1$ and 311.2 in the MS
27 spectrum which match with the species $[(\text{PZQ-OH})+\text{H}]^+$ and $[(\text{PZQ-OH})-\text{H}_2\text{O}+\text{H}]^+$, respectively.
28
29 This metabolite **1.M2** was confirmed to be the *cis*-4-hydroxypraziquantel (*cis*-4-PZQ-OH,
30 Scheme 1) by comparing the LC-MS traces of the synthetic standards *cis*-4-PZQ-OH and *trans*-
31 4-hydroxypraziquantel (*trans*-4-PZQ-OH) (Figure S1 in SI).¹⁶ The other three minor metabolites
32 were detected at retention times of 10.1 (**1.M3**), 10.5 (**1.M4**) and 10.9 (**1.M5**) minutes (Figure 2
33 and Table S1). Metabolites **1.M3** and **1.M4** have a similar mass spectrum with an intense peak at
34 $m/z = 465.1$ (Table S1) that matches well the protonated adduct of mono-hydroxylated species of
35 **1** (Scheme 1). As they are present as trace metabolites in the mixture, further efforts were not
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

made to confirm the structure of these metabolites. The hydroxylation of **1**, most likely, occurs in the cyclohexane ring or at the tetrahydroisoquinoline part. The minor metabolite **1.M5** also has a similar mass spectrum pattern to PZQ-OH with a central peak at $m/z = 329.2$, which corresponds to another mono-hydroxylated derivative of PZQ (see Table S1). Although we could confirm, by comparing the UV traces from LC-MS analysis, that **1.M5** is not the *trans*-4-PZQ-OH (Figure S1 in SI), we could not structurally characterize **1.M5** due to a lack of any standard matching compound. However, as reported earlier, the hydroxylation in **1.M5** is expected to occur either at the tetrahydroquinoline part or at the aromatic ring of PZQ.¹⁷ A plausible metabolic profile of **1** explaining the possible routes of formation of metabolites is presented in Scheme 1(a).





Figure 2. UV traces at 220 nm of LC analysis of **1** (left, a and b) and **2** (right, c and d) treated with human liver microsomes at $t = 0$ min and at $t = 2.5$ h.





Scheme 1. Suggested metabolic profiles of **1** (a) and **2** (b) explaining possible routes to form the different metabolites.

Metabolism rate and profile data were obtained for compound **2** that were significantly different to those obtained for **1** (Figure 2, right, c) and d) and Table S2). A metabolic profile of **2** is schematically presented in Scheme 1. Only a trace amount of **2** was present in the microsomes/NADPH mixture after 2.5 h (Table S3). The most abundant metabolite **2.M1** (ca. 43%) was detected at a retention time of 7.9 minutes. The corresponding ESI-MS peak at $m/z = 339.0$ matches well the calculated molecular weight of the protonated species of $[(\eta^6\text{-Praziquanamine})\text{Cr}(\text{CO})_3]$ (**3**), i. e. $[\mathbf{3}+\text{H}]^+$ (calculated $m/z = 339.01$). Metabolite **3** can only be formed by the cleavage of the amide bond between Praziquanamine and the cyclohexanoyl moiety of **2**. This type of amide bond cleavage was not observed in the case of **1**. The formation of **3** was further confirmed by comparing the UV trace of the synthetic standard (See Figure S2 and Scheme 2 for synthetic details). Formation of six other less abundant metabolites, **2.M2** (*trans*-4-PZQ-OH), **1.M2** (*cis*-4-PZQ-OH), **2.M3** (2-OH), **1.M5** (PZQ-OH) and **1.M1** (PZQ)

1
2
3
4
5
6 was also observed and these were characterized from their corresponding UV traces and ESI-MS
7 spectra (see Figure S2 and Table S2 in SI).
8

9
10 The metabolism study of **1** and **2** was authenticated by carrying out a metabolic study on PZQ
11 itself using the same assay as for **1** and **2** and by further comparison with previously reported
12 results.¹⁷⁻²² As shown in Figure S3 in SI, PZQ was exclusively metabolized to its mono-
13 hydroxylated species **1.M2** (*cis*-4-PZQ-OH) and **1.M5** (an unidentified mono-hydroxylated
14 derivative). This observation is in good agreement with reports described earlier.^{17, 22} Formation
15 of a trace amount of *trans*-4-PZQ-OH was also observed.
16
17

18
19 Of note, using the experimental conditions and LC-MS setup reported in this study, we did not
20 observe the presence of any dehydrogenated metabolites for PZQ, **1** and **2**, as previously reported
21 for PZQ by Alnouti, Kiec-Kononowicz and co-workers using different analytical techniques
22 and/or a slightly different *in vitro* model (human cytochrome P-450 3A4 expressed in
23 *Escherichia coli* and *Saccharomyces cerevisiae* instead of microsomes).^{8, 23} Although we were
24 unable to detect any of these metabolites, the possibility of their formation cannot be completely
25 ruled out. One can speculate that the dehydrogenated compounds could be formed as minor
26 metabolites that co-elute with a major metabolite and that the MS only detects the more abundant
27 component present in the mixture.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Scheme 2. Synthesis of **3** and optically pure $(\eta^6\text{-PZQ})\text{Cr(CO)}_3$ derivatives. Note that Praziquanamine, **3** and Iso-**3** are racemates.

***In Vitro* Antischistosomal Activity Studies of Optically pure $(\eta^6\text{-PZQ})\text{Cr(CO)}_3$ derivatives**

and selected metabolites of 1 and 2. In order to assess if only one enantiomer of compounds **1** and **2** were active against *S. mansoni* (as is the case for PZQ) the optically pure $(\eta^6\text{-PZQ})\text{Cr(CO)}_3$ derivatives were prepared using a similar synthetic pathway as for *rac*-**1** and **2** (see Scheme 2 for details).¹⁵ Optically pure PZQ (*S*-PZQ and *R*-PZQ),²⁴ was employed as starting material (see Figures S4-9 in the SI for chiral HPLC traces). The four new complexes, namely (*S*, *Sp*)-**1**, (*R*, *Rp*)-**1**, (*S*, *Rp*)-**2** and (*R*, *Sp*)-**2** were tested against adult schistosomes *in vitro* (Table 1). Enantioselective antischistosomal activity was observed for both derivatives. Only the (*R*)-enantiomers exhibited high levels of activity: (*R*, *Rp*)-**1** with an IC_{50} value of 0.08

1
 2
 3
 4
 5
 6 μM and (*R*, *Sp*)-**2** with 0.13 μM . Both (*S*)-enantiomers lacked activity ($\text{IC}_{50} > 66.9 \mu\text{M}$). The *in vitro*
 7
 8 activity of the major metabolites elucidated for **1** and **2** was likewise tested. As expected,
 9
 10 high activity was observed for **1.M1** (PZQ) (IC_{50} : 0.1 μM). The second major metabolite of **1**
 11
 12 (**1.M2**) showed good but 24-fold decreased antischistosomal activity (IC_{50} : 5.9 μM) when
 13
 14 compared to the parent drug. The major chromium-containing metabolite of **2**, **2.M1**, presented
 15
 16 only moderate activity with an IC_{50} value of 11.6 μM . Taken together, the remarkably
 17
 18 enantioselective antischistosomal activities observed during the *in vitro* experiments are a good
 19
 20 indication that (*R*, *Rp*)-**1** and (*R*, *Sp*)-**2** act on the same target(s) as PZQ.^{8, 25}
 21
 22
 23
 24
 25

26 **Table 1.** *In vitro* activity of compounds **1** and **2**, the optically pure enantiomers of **1** and **2** and
 27
 28 the main metabolites of **1** (**1.M1**, **1M.2**) and **2** (**2.M1**) against adult *S. mansoni*. ‘R’ represents
 29
 30 the “Goodness of fit” which has to be ≥ 0.85)
 31
 32

	Compound ^[a]	IC_{50} [μM]	R
Parent compounds	1 ^[b]	0.25	1.0
	2 ^[b]	0.27	1.0
	PZQ	0.10	1.0
Optically pure derivatives	(<i>R</i> , <i>Rp</i>)- 1	0.08	0.9
	(<i>S</i> , <i>Sp</i>)- 1	> 66.9	
	(<i>R</i> , <i>Sp</i>)- 2	0.13	1.0
	(<i>S</i> , <i>Rp</i>)- 2	> 66.9	
Major metabolites	1.M1 (PZQ)	0.1	1.0
	<i>Cis</i> -4-PZQ-OH (1.M2)	5.9	0.9
	3 (2.M1)	11.6	0.9

46 [a] Note that **1**, **2**, PZQ, *Cis*-4-PZQ-OH (**1.M2**) and **3** (**2.M1**) are racemates; [b] data published
 47 by Patra *et al.*¹⁵
 48
 49
 50
 51
 52
 53

54 **In Vivo Antischistosomal Activity Studies.** To assess the *in vivo* potential of the chromium
 55
 56 tricarbonyl derivatives, **1** and **2** were given orally to mice harboring a chronic *S. mansoni*
 57
 58 infection. The racemate mixtures of **1** and **2** were given to mice for comparison purposes with
 59
 60

PZQ, which is itself given as a racemate. The results are summarized in Table 2. Treatment of mice at a single dose of 400 mg/kg of **1** and **2** resulted in low worm burden reductions of 24 and 29 % ($p > 0.05$), respectively. In the treatment group of compound **1**, two mice died one day post-treatment whereas one of the mice treated with **2** died 4 days post-treatment. For comparison, at this dose (400 mg/kg) worm burden reductions of 96% are achieved with PZQ.²⁶ The toxicity observed was unexpected as **1** and **2** did not present any cytotoxicity on the non-cancerous cell line MRC-5 up to 100 μM compound concentration.¹⁵ The low *in vivo* activity observed can be attributed to the metabolic lability of **1** and **2** resulting in less active metabolites (Table 2). It is interesting that both compounds exert a similar low *in vivo* activity despite compound **1** being metabolized to PZQ. However, since *S. mansoni* live in the mesenteric veins they might not be exposed to PZQ before it is metabolised in the liver through first-pass. It can also be hypothesized that the relatively low *in vivo* activity observed is due to protein binding or distribution problems. Further experiments outside the scope of this article should be undertaken to evaluate these assumptions.

Table 2. *In vivo* activity of two racemic ($\eta^6\text{-PZQ}$)Cr(CO)₃ derivatives **1** and **2** administered at single oral doses of 400 mg/kg to mice harbouring adult *S. mansoni*.

Group	No. of mice investigated	No. of mice cured	Mean number of worms (SD)	TWR [%]	p-value
Control	9	-	36.7 (8.2)	-	-
1	5 ^[a]	0	28 (5.9)	24	>0.05
2	5 ^[b]	0	26.3 (19.9)	29	>0.05
PZQ	N/A	N/A	N/A	96 ^[c]	N/A

[a] 2 mice died 24 h post-treatment; [b] 1 mouse died 96 h post-treatment; [c] taken from Dong *et al.*³¹ N/A: Not available; SD: Standard Deviation; TWR: Total worm burden reduction.

Conclusions

Taken together, the low *in vivo* antischistosomal activity as well as toxicity observed for **1** and **2** compared to PZQ contrast with the remarkable *in vitro* results previously described¹⁵ and further emphasize the necessity for *in vivo* confirmation of *in vitro* hits. It is important to note that the toxicity observed cannot be at least fully attributed to chromium toxicity but might instead have been caused by the schistosome infection. The amount of chromium given to the mice (400 mg/kg of (η^6 -PZQ)Cr(CO)₃ derivatives), assuming a full release of chromium from **1** and **2** as well as the oxidation of Cr(0) to the more *in vivo* stable Cr(III), is insufficient to kill mice: the LD₅₀ values of Cr(III) salts are 3.2-15 g/kg, when administered orally in rats.²⁷ Of note, Cr(III) has even been used as an antidiabetic agent.²⁸

In summary in this study we have demonstrated, using human liver microsomes, that two (η^6 -PZQ)Cr(CO)₃ derivatives, which were previously shown to have *in vitro* activity against *S. mansoni* comparable to PZQ, were metabolically labile. Clear differences in the rate of metabolism and identity of the metabolites produced were observed between **1** and **2**. Indeed, while **1** was metabolized slowly and produced PZQ and PZQ-OH as the most abundant metabolites, **2** was mostly metabolized to **3** and to a lesser extent to PZQ and PZQ-OH. Importantly, an enantioselective *in vitro* antischistosomal activity comparable to PZQ itself was determined for the organometallic compounds **1** and **2**. These results are a good indication that the active form of **1** and **2** bind to the same target(s) as PZQ. Finally, *in vivo* experiments demonstrated that low worm burden reductions of 24 and 29 % ($p > 0.05$) were obtained when a single dose of **1** and **2** (400 mg/kg) were given to mice harboring a chronic *S. mansoni* infection. Overall the results presented herein will give valuable information to the rapidly growing field of medicinal organometallic chemistry field.²⁹ As highlighted by Hartinger, Metzler-Nolte and

1
2
3
4
5
6
7 Dyson in a recent review about organometallic anticancer compounds, there is an important lack
8
9 of published *in vivo* studies on non-radioactive bioorganometallic compounds.³⁰ We therefore do
10
11 believe that the work presented in this study will help to fill this important gap and hopefully
12
13 allow more organometallic compounds to become part of drug research and development.
14
15
16
17

18 19 **Experimental section.**

20
21 **Materials.** All chemicals were of reagent grade quality or better, obtained from commercial
22
23 suppliers and used without further purification. Solvents were used as received or dried over
24
25 molecular sieves. All preparations were carried out using standard Schlenk techniques. **1**, **2**,
26
27 praziquanamine, *trans*-4-PZQ-OH and *cis*-4-PZQ-OH, *R*-PZQ and *S*-PZQ were prepared
28
29 following standard literature procedures.^{15, 16, 24, 31, 32} The optically pure four (η^6 -PZQ)Cr(CO)₃
30
31 derivatives were prepared using *R*-PZQ and *S*-PZQ following a procedure reported for synthesis
32
33 of **1** and **2**.¹⁵ The purities of compounds (**1**, **2**, (*S*, *Sp*)-**1**, (*R*, *Rp*)-**1**, (*S*, *Rp*)-**2** and (*R*, *Sp*)-**2** and **3**,
34
35 and *cis*-4-PZQ-OH) used for biological activity were checked by elemental analysis. The
36
37 enantio-purities of (*S*, *Sp*)-**1**, (*R*, *Rp*)-**1**, (*S*, *Rp*)-**2** and (*R*, *Sp*)-**2** were checked using chiral HPLC
38
39 technique and the enantiopurities was found to be $\geq 95\%$.
40
41
42
43

44
45 **Instrumentation and Methods.** ¹H and ¹³C NMR spectra were recorded in deuterated solvents
46
47 on 400 (¹H: 400 MHz, ¹³C: 100.6 MHz) or 500 (¹H: 500 MHz, ¹³C: 126 MHz) MHz
48
49 spectrometers at room temperature. The chemical shifts, δ , are reported in ppm (parts per
50
51 million). The residual solvent peaks have been used as an internal reference. The abbreviations
52
53 for the peak multiplicities are as follows: s (singlet), d (doublet), dd (doublet of doublets), t
54
55 (triplet), q (quartet), m (multiplet), and br (broad). Infrared spectra were recorded on Perkin-
56
57 Elmer ATR-FTIR spectrometer. ESI mass spectra were recorded using a Bruker ESQUIRE 6000
58
59
60

1
2
3
4
5
6 HCT quadrupole ion trap instrument (Bruker Daltonik GmbH, Leipzig, Germany), equipped
7
8 with an electrospray ionization source. Waters ACQUITY ultra performance LC (Waters,
9
10 Baden-Dätwill, Switzerland) with a diode array detector was directly interfaced to the ESI ion
11
12 source. *LC-MS measurements* were run in the following conditions: alternating polarity,
13
14 nebulizer gas (N₂) 35 psi, dry gas (N₂) 8 l/min, dry temperature 350°C, HV capillary 4000 V,
15
16 HV EndPlate offset -500 V, capillary exit 166 V, skimmer 40 V, trap drive 80, mass range from
17
18 m/z 100 to 2000. For metabolism studies, the Nucleosil 100-5 C18 (250 × 3 mm) reverse phase
19
20 column was used with a flow rate of 0.5 mL min⁻¹ and UV-absorption was measured at 220 nm.
21
22 The runs were performed with a linear gradient of A (acetonitrile (Sigma-Aldrich HPLC-grade)
23
24 and B (distilled water containing 0.02% TFA and 0.05% HCOOH): t = 0-3 min, 20% A;
25
26 t = 7 min, 50% A; t = 16 min, 80% A; t = 19 min, 100% A; t = 22 min, 100% A; t = 25 min, 20%
27
28 A. The level of enantioenrichment of compounds was checked using a Chiralpak® IC
29
30 (250 × 4.6 mm) column fitted to a HPLC apparatus (*HITACHI chromaster*). The runs were
31
32 performed with a linear gradient of A (acetonitrile (Sigma-Aldrich HPLC-grade) and B (distilled
33
34 water): t = 0-3 min, 70% A; t = 7 min, 90% A; t = 16 min, 90% A; t = 20 min, 100% A; t =
35
36 25 min, 100% A; t = 28 min, 70% A. A flow rate of 1 mL min⁻¹ was used and UV-absorption
37
38 was recorded at 250 nm.
39
40
41
42
43
44

45 **Determination of *in vivo* activity against *Schistosoma mansoni*.** Studies were approved by the
46
47 local veterinary agency (permission no. 2070). Female NMRI mice (n=19, obtained from Harlan
48
49 Laboratories (Horst, the Netherlands)), were subcutaneously infected with ~ 100 cercariae
50
51 following standard procedures.³³ Groups of 5 infected NMRI mice characterized by a patent *S.*
52
53 *mansoni* infection (49 days post-infection) were treated orally with the test drugs using single
54
55 oral doses (400 mg/kg). Untreated mice (n=9) served as controls. Fourteen days post-treatment
56
57
58
59
60

1
2
3
4
5
6 animals were sacrificed by the CO₂ method and dissected. Worms were sexed and counted.³⁴
7
8
9 Worm burdens of treated mice were compared to control animals and reductions of worm burden
10
11 calculated. To compare the medians of the responses between the treatment and control groups
12
13 the Kruskal-Wallis test was utilized. A difference in median was considered to be significant at a
14
15 significance level of 5%.
16

17 **Determination of *in vitro* activity against *Schistosoma mansoni*.**

18
19
20 Schistosomes were cultured in RPMI 1640 culture medium (supplemented with 5% inactivated
21
22 fetal calf serum (iFCS) and 100 U/mL penicillin as well as 100 µg/mL streptomycin (Invitrogen,
23
24 Carlsbad, USA)) at 37 °C in an atmosphere of 5% CO₂. All compounds of interest were tested at
25
26 a concentration range of 0.11 - 30 µg/ml (0.11, 0.33, 1.1, 3.3, 10 and 30 µg/ml), using DMSO
27
28 stock solutions (conc. 10 mg/ml; final concentration of DMSO: 0.3 %) diluted in supplemented
29
30 RPMI 1640 medium within 24 flat bottom well plates (BD Falcon, USA) with a final volume of
31
32 2 ml per well.³⁵ Three worms of both sexes, were placed into each well. Wells with the highest
33
34 concentration of DMSO in medium served as controls. Praziquantel served as positive control.
35
36 Phenotypes were monitored after 72 h using the motility scale described by Ramirez *et al.*³⁶ and
37
38 an inverse microscope (Carl Zeiss, Germany, magnification 80x). Each experiment was
39
40 performed three times. IC₅₀ values of active compounds and positive control were calculated
41
42 using CompuSyn software (Version 3.0.1, 2007; ComboSyn, Inc) as described before.³⁵
43
44
45
46

47 **Metabolic stability studies.** Human microsomes (Gibco) at a concentration of 20 mg/ml were
48
49 slowly thawed on ice. 10 µl microsomes (0.46 mg/ml final concentration) were then incubated in
50
51 a water bath with 382 µl of 100 mM phosphate buffer (pH 7.4), 4 µl of a 20 mM NADPH
52
53 solution, 2.5 µl of the tested compound (stock solution: 5 mM in DMSO, final concentration 0.03
54
55 mM) and 2.5 µl of Diazepam (stock solution: 1 mM in DMSO; final concentration 0.006 mM)
56
57
58
59
60

1
2
3
4
5
6 for 5 min at 37°C. Following this, the reaction was initiated by adding another 30 μ l of a 20 mM
7
8 NADPH solution (1.6 mM final concentration), the mixture was then incubated for required time
9
10 at 37°C while shaking slowly (final DMSO concentration: 1.16 %). The reaction was then
11
12 stopped by addition of 2 ml CH_2Cl_2 . Sample was vortex and centrifuged for 5 min at 1000xg.
13
14 The CH_2Cl_2 layer was taken up carefully and evaporated using a N_2 -flow. The residue was
15
16 dissolved in 100 μ l of 8:5 ACN:H₂O (containing 0.02% TFA + 0.05% HCOOH) and 40 μ l was
17
18 injected in LC-MS.
19
20
21

22
23 (η^6 -Praziquanamine) $\text{Cr}(\text{CO})_3$ (**3**). A solution of praziquanamine (298 mg, 1.48 mmol) in 30 mL
24
25 of $\text{Bu}_2\text{O}/\text{THF}$ (8:1) was degassed by two freeze-thaw cycles. $\text{Cr}(\text{CO})_6$ (488 mg, 2.2 mmol) was
26
27 added to the solution and was degassed again by one more freeze-thaw cycle. The reaction
28
29 mixture was heated at 140°C under a nitrogen atmosphere in dark for 30 h. The resulting yellow
30
31 solution was then cooled to room temperature and solvent was removed, the residue was re-
32
33 dissolved in CH_2Cl_2 and filtered through a celite pad and concentrated. The residue was
34
35 subjected to silica column chromatography for two times (eluent: $\text{EtOAc}:\text{MeOH}:\text{NEt}_3$ 20:1:0 \rightarrow
36
37 10:1:0.1 \rightarrow 10:2:0.3) to remove the impurities and minor isomer Iso-**3**. Compound **3** was obtain
38
39 as yellow solid (70 mg, 14%). Retention time = 7.9 min (RP-HPLC). ^1H NMR (500 MHz,
40
41 CDCl_3): δ (ppm) 2.61-2.65 (m, 1H), 2.82-3.01 (m, 3H), 3.61-3.69 (m, 3H), 4.61-4.79 (m, 2H),
42
43 5.15-5.27 (m, 2H), 5.39 (m, 1H), 5.51 (m, 1H). ^{13}C NMR (126 MHz, CDCl_3): δ (ppm) 27.1,
44
45 38.9, 50.1, 50.4, 53.2, 88.2, 89.9, 90.1, 92.4, 108.1, 109.7, 157.1, 232.1. ESI-MS (pos. detection
46
47 mode): m/z (%): 339.1 (100) $[\text{M}+\text{H}]^+$. IR bands(ν): 1940 and 1855 ($\text{Cr}-\text{CO}$) cm^{-1} . Anal. calcd.
48
49 for $\text{C}_{15}\text{H}_{14}\text{CrN}_2\text{O}_4 \cdot \text{MeOH}$: C 52.54, H 4.55, N 7.91. Found: C 52.37, H 4.59, N 7.84.
50
51
52
53
54
55
56
57

58 ASSOCIATED CONTENT
59
60

1
2
3
4
5
6 **Supporting Information.** UV traces at 220 nm of the LC-MS analysis of **1**, **2** and PZQ after
7
8 incubated with human liver microsome (Figures S1-S3). Tables showing the detection of the
9
10 metabolites of **1** and **2** by LC-MS (Table S1-S2). Chiral HPLC traces of optically pure PZQ and
11
12 (η^6 -PZQ)Cr(CO)₃ (Figures S4-S9). This material is available free of charge via the Internet at
13
14 <http://pubs.acs.org>
15
16

17 18 19 AUTHOR INFORMATION

20 21 **Corresponding Authors**

22
23 *E-mail: jennifer.keiser@unibas.ch; Fax: +41 61 284 81 01; Tel: +41 61 284 82 18; Email:
24
25 gilles.gasser@aci.uzh.ch; Fax: +41 44 635 6803; Tel: +41 44 635 4630; WWW:
26
27 www.gassergroup.com.
28
29

30 31 **Author Contributions**

32
33 The manuscript was written through contributions of all authors. All authors have given approval
34
35 to the final version of the manuscript.
36
37

38 39 ACKNOWLEDGMENT

40
41 This work was financially supported by the Swiss National Science Foundation (SNSF
42
43 Professorships PP00P2_133568 to G.G. and PP00P3-135170 to J.K.), the Scientific &
44
45 Technological Cooperation Program Switzerland-Russia (J.K.), the University of Zurich (G.G.
46
47 and S.F.), the Stiftung für Wissenschaftliche Forschung of the University of Zurich (G.G. and
48
49 S.F.), the Stiftung zur Krebsbekämpfung (S.F), the Huggenberger-Bischoff Stiftung (S.F), the
50
51 University of Zurich Priority Program (S.F.), the Australian Research Council (Linkage Grant
52
53 LP0883419) and the UNICEF/UNPD/World Bank/WHO Special Programme for Research and
54
55 Training (TDR) grants A70050 and A90461 (M.N.R. and M.H.T.).
56
57
58
59
60

Abbreviations.

ACN: Acetonitrile; PZQ: Praziquantel; (η^6 -PZQ)Cr(CO)₃: Chromium tricarbonyl derivative of Praziquantel; *cis*-4-PZQ-OH: *cis*-4-hydroxypraziquantel; *trans*-4-PZQ-OH: *trans*-4-hydroxypraziquantel; 1-OH: Monohydroxylated derivative of **1**; 2-OH: Monohydroxylated derivative of **2**; LC-MS: Liquid Chromatography-Mass Spectrometry; MW: Molecular Weight.

REFERENCES

1. Gryseels, B. Schistosomiasis. *Infect. Dis. Clin. North Am.*, **2012**, *26*, 383-397.
2. Steinmann, P.; Keiser, J.; Bos, R.; Tanner, M.; Utzinger, J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *The Lancet Infect. Dis.*, **2006**, *6*, 411-425.
3. Thétiot-Laurent, S. A. L.; Boissier, J.; Robert, A.; Meunier, B. Schistosomiasis Chemotherapy. *Angew. Chem. Int. Ed.*, **2013**, *52*, 7936-7956.
4. Ismail, M.; Botros, S.; Metwally, A.; William, S.; Farghally, A.; Tao, L. F.; Day, T. A.; Bennett, J. L. Resistance to praziquantel: direct evidence from *Schistosoma mansoni* isolated from Egyptian villegers. *Am. J. Trop. Med. Hyg.*, **1999**, *60*, 932-935.
5. Melman, S. D.; Steinauer, M. L.; Cunningham, C.; Kubatko, L. S.; Mwangi, I. N.; Wynn, N. B.; Mutuku, M. W.; Karanja, D. M. S.; Colley, D. G.; Black, C. L.; Secor, W. E.; Mkoji, G. M.; Loker, E. S. Reduced Susceptibility to Praziquantel among Naturally Occurring Kenyan Isolates of *Schistosoma mansoni*. *PLoS Negl. Trop. Dis.*, **2009**, *3*, e504.
6. Greenberg, R. M. New approaches for understanding mechanisms of drug resistance in schistosomes. *Parasitology*, **2013**, *140*, 1534-1546.
7. Cioli, D.; Pica-Mattoccia, L.; Archer, S. Antischistosomal drugs: past, present . . . and future? . *Pharmacol. Ther.*, **1995**, *68*, 35-85.

- 1
2
3
4
5
6 8. Huang, J.; Bathena, S. P. R.; Alnouti, Y. Metabolite Profiling of Praziquantel and its
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Analogues During the Analysis of in vitro Metabolic Stability Using Information-Dependent
Acquisition on a Hybrid Triple Quadrupole Linear Ion Trap Mass Spectrometer. *Drug
Metab. Pharmacokinet.*, **2010**, *25*, 487-499.
9. Doenhoff, M. J.; Cioli, D.; Utzinger, J. Praziquantel: mechanisms of action, resistance and
new derivatives for schistosomiasis. *Curr. Opin. Infect. Dis.*, **2008**, *21*, 659-667.
10. Hillard, E. A.; Vessières, A.; Jaouen, G. Ferrocene functionalized endocrine modulators as
anticancer agents. In *Medicinal Organometallic Chemistry*, Jaouen, G.; Metzler-Nolte, N.,
Eds. Springer-Verlag: Heidelberg, 2010; Vol. 32, pp 81-117.
11. Dive, D.; Biot, C. Ferrocene conjugates of chloroquine and other antimalarials: the
development of ferroquine, a new antimalarial. *ChemMedChem*, **2008**, *3*, 383 - 391.
12. Hillard, E.; Vessieres, A.; Thouin, L.; Jaouen, G.; Amatore, C. Ferrocene-mediated proton-
coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates.
Angew. Chem. Int. Ed., **2006**, *45*, 285–290.
13. Dubar, F.; Egan, T. J.; Pradines, B.; Kuter, D.; Ncokazi, K. K.; Forge, D.; Paul, J.-F. o.;
Pierrot, C.; Kalamou, H.; Khalife, J.; Buisine, E.; Rogier, C.; Vezin, H.; Forfar, I.;
Slomianny, C.; Trivelli, X.; Kapishnikov, S.; Leiserowitz, L.; Dive, D.; Biot, C. The
Antimalarial Ferroquine: Role of the Metal and Intramolecular Hydrogen Bond in Activity
and Resistance. *ACS Chem. Biol.*, **2012**, *6*, 275-287.
14. Patra, M.; Ingram, K.; Pierroz, V.; Ferrari, S.; Spingler, B.; Keiser, J.; Gasser, G.
Ferrocenyl Derivatives of the Anthelmintic Praziquantel: Design, Synthesis and Biological
Evaluation. *J. Med. Chem.*, **2012**, *55*, 8790-8798.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15. Patra, M.; Ingram, K.; Pierroz, V.; Ferrari, S.; Spingler, B.; Gasser, R. B.; Keiser, J.; Gasser, G. (η^6 -Praziquantel)Cr(CO)₃ Derivatives with Remarkable In Vitro Antischistosomal Activity. *Chem. Eur. J.*, **2013**, *19*, 2232-2235.
16. Kiec-Kononowicz, K.; Farghaly, Z. S.; Blaschke, G. Synthesis and Properties of cis- and trans-4-Hydroxypraziquantel. *Arch. Pharm. (Weinheim)*, **1991**, *324*, 235-237.
17. Lerch, C.; Blaschke, G. Investigation of the stereoselective metabolism of praziquantel after incubation with rat liver microsomes by capillary electrophoresis and liquid chromatography–mass spectrometry. *J. Chromatogr. B*, **1998**, *708*, 267-275.
18. Diekmann, H. W. Quantitative determination of praziquantel in body fluids by gas liquid chromatography. *Eur. J. Drug Metab. Pharmacokinet.*, **1979**, *4*, 139-141.
19. Andrews, P.; Thomas, H.; Pohlke, R.; Seubert, J. Praziquantel. *Med. Res. Rev.*, **1983**, *3*, 147-200.
20. Steiner, K.; Garbe, A.; Diekmann, H. W.; Nowak, H. The fate of praziquantel in the organism I. Pharmacokinetics in animals. *Eur. J. Drug Metab. Pharmacokin.*, **1976**, *1*, 85-95.
21. Meier, H.; Blaschke, G. Investigation of Praziquantel metabolism in isolated rat hepatocytes. *J. Pharm. Biomed. Anal.*, **2001**, *26*, 409-415.
22. Schepmann, D.; Blaschke, G. Isolation and identification of 8-hydroxypraziquantel as a metabolite of the antischistosomal drug praziquantel. *J. Pharm. Biomed. Anal.*, **2001**, *26*, 791-799.
23. Godawska-Matysik, A.; Kieć-Kononowicz, K. Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4). *Acta pol. pharm.*, **2006**, *63*, 381-385.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24. Woelfle, M.; Seerden, J.-P.; de Gooijer, J.; Pouwer, K.; P., O.; Todd, M. H. Resolution of Praziquantel. *PLoS Negl. Trop. Dis.*, **2011**, *5*, e1260.
25. Chan, J. D.; Zarowiecki, M.; Marchant, J. S. Ca(2+) channels and Praziquantel: A view from the free world. *Parasitol Int.*, **2012**, DOI: 10.1016/j.parint.2012.12.001.
26. Keiser, J.; Chollet, J.; Xiao, S.-H.; Mei, J.-Y.; Jiao, P.-Y.; Utzinger, J.; Tanner, M. Mefloquine - An Aminoalcohol with Promising Antischistosomal Properties in Mice. *PLoS Negl. Trop. Dis.*, **2009**, *3*, e350.
27. Assem, L.; Zhu, H. *Chromium; toxicological overview*, **2007**, Health Protection Agency, http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947362170.
28. Levina, A.; Lay, P. A. Metal-based anti-diabetic drugs: advances and challenges. *Dalton Trans.*, **2011**, *40*, 11675-11686; and references there in.
29. Jaouen, G.; Metzler-Nolte, N. Medicinal Organometallic Chemistry. In *Topics in Organometallic Chemistry*, 1st ed.; Springer: Heidelberg, Germany, 2010; Vol. 32.
30. Hartinger, C. G.; Metzler-Nolte, N.; Dyson, P. J. Challenges and Opportunities in the Development of Organometallic Anticancer Drugs. *Organometallics*, **2012**, *31*, 5677-5685.
31. Dong, Y.; Chollet, J.; Vargas, M.; Mansour, N. R.; Bickle, Q.; Alnouti, Y.; Huang, J.; Keiser, J.; Vennerstrom, J. L. Praziquantel analogs with activity against juvenile *Schistosoma mansoni*. *Bioorg. Med. Chem. Lett.*, **2010**, *20*, 2481-2484.
32. Laurent, S. A.-L.; Boissier, J.; Coslédan, F.; Gornitzka, H.; Robert, A.; Meunier, B. Synthesis of “Trioxaquantel”® derivatives as potential new antischistosomal drugs. *Eur. J. Org. Chem.*, **2008**, 895-913.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
33. Keiser, J. In vitro and in vivo trematode models for chemotherapeutic studies. *Parasitology*, **2009**, *137*, 589–603.
34. Xiao, S.-H.; Keiser, J.; Chollet, J.; Utzinger, J.; Dong, Y.; Endriss, Y.; J.L., V.; Tanner, M. In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. *Antimicrob. Agents Chemother.*, **2007**, *51*, 1440–1445.
35. Ingram, K.; Ellis, W.; Keiser, J. Antischistosomal activities of mefloquine-related arylmethanols. *Antimicrob. Agents Chemother.*, **2012**, *56*, 3207-3215.
36. Ramirez, B.; Bickle, Q.; Yousif, F.; Fakorede, F.; Mouries, M.-A.; Nwaka, S. Schistosomes: challenges in compound screening. *Expert Opin. Drug Discov.*, **2007**, *2*, S53-S61.

TOC Figure.

